Mural Oncology
Karim Younan is a seasoned professional in the biopharmaceutical industry with extensive experience in technical development, operations, and supply chain management, currently serving as Vice President of Technical Development & Operations at Mural Oncology. Previous roles include Vice President at 2seventy bio, overseeing global supply chain and CMC strategy for oncology therapies, and earlier leadership positions at bluebird bio and Merck, where Karim managed operations, external manufacturing, and supply chain for critical drug products and vaccines. Karim holds a Bachelor's Degree in Chemical Engineering from the University of Delaware and has demonstrated expertise in strategic planning, regulatory compliance, cross-functional collaboration, and efficient tech transfer throughout a career spanning over two decades.
This person is not in any teams
Mural Oncology
2 followers
We know that drug development is both an art and a science. The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us. Our mission is simple, to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living. Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies. We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective. Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)